Ionis Pharmaceuticals, Inc. (IONS)

$38.97

-0.71

(-1.79%)▲

Live

Performance

  • $38.36
    $39.55
    $38.97
    downward going graph

    1.57%

    Downside

    Day's Volatility :3.01%

    Upside

    1.47%

    downward going graph
  • $35.95
    $54.44
    $38.97
    downward going graph

    7.75%

    Downside

    52 Weeks Volatility :33.97%

    Upside

    28.42%

    downward going graph

Returns

PeriodIonis Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-21.6%
3.6%
0.0%
6 Months
-3.38%
10.2%
0.0%
1 Year
-13.34%
19.6%
0.0%
3 Years
30.83%
16.8%
-23.0%

Highlights

Market Capitalization
6.1B
Book Value
$1.81
Earnings Per Share (EPS)
-2.52
PEG Ratio
25.7
Wall Street Target Price
61.72
Profit Margin
-44.96%
Operating Margin TTM
-29.34%
Return On Assets TTM
-7.58%
Return On Equity TTM
-105.71%
Revenue TTM
813.5M
Revenue Per Share TTM
5.63
Quarterly Revenue Growth YOY
19.6%
Gross Profit TTM
-257.9M
EBITDA
-330.7M
Diluted Eps TTM
-2.52
Quarterly Earnings Growth YOY
-0.44
EPS Estimate Current Year
-3.67
EPS Estimate Next Year
-3.64
EPS Estimate Current Quarter
-0.92
EPS Estimate Next Quarter
-0.96

Analyst Recommendation

Buy
    66%Buy
    23%Hold
    10%Sell
Based on 30 Wall street analysts offering stock ratings for Ionis Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 30 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
20
19
19
Hold
7
8
7
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 58.38%

Current $38.97
Target $61.72

Company Financials

FY18Y/Y Change
Revenue
599.7M
↑ 18.12%
Net Income
273.7M
↓ 4685.28%
Net Profit Margin
45.65%
↑ 46.83%
FY19Y/Y Change
Revenue
1.1B
↑ 87.27%
Net Income
294.0M
↑ 7.4%
Net Profit Margin
26.18%
↓ 19.47%
FY20Y/Y Change
Revenue
729.0M
↓ 35.08%
Net Income
-487.0M
↓ 265.65%
Net Profit Margin
-66.8%
↓ 92.98%
FY21Y/Y Change
Revenue
810.0M
↑ 11.11%
Net Income
-29.0M
↓ 94.05%
Net Profit Margin
-3.58%
↑ 63.22%
FY22Y/Y Change
Revenue
587.0M
↓ 27.53%
Net Income
-270.0M
↑ 831.03%
Net Profit Margin
-46.0%
↓ 42.42%
FY23Y/Y Change
Revenue
787.6M
↑ 34.18%
Net Income
-366.3M
↑ 35.66%
Net Profit Margin
-46.5%
↓ 0.5%
Q1 FY23Q/Q Change
Revenue
131.0M
↓ 13.82%
Net Income
-124.0M
↑ 138.46%
Net Profit Margin
-94.66%
↓ 60.45%
Q2 FY23Q/Q Change
Revenue
188.0M
↑ 43.51%
Net Income
-85.0M
↓ 31.45%
Net Profit Margin
-45.21%
↑ 49.45%
Q3 FY23Q/Q Change
Revenue
144.0M
↓ 23.4%
Net Income
-147.0M
↑ 72.94%
Net Profit Margin
-102.08%
↓ 56.87%
Q4 FY23Q/Q Change
Revenue
324.5M
↑ 125.35%
Net Income
-9.3M
↓ 93.7%
Net Profit Margin
-2.85%
↑ 99.23%
Q1 FY24Q/Q Change
Revenue
119.5M
↓ 63.18%
Net Income
-142.8M
↑ 1441.65%
Net Profit Margin
-119.5%
↓ 116.65%
Q2 FY24Q/Q Change
Revenue
225.3M
↑ 88.5%
Net Income
-66.3M
↓ 53.6%
Net Profit Margin
-29.42%
↑ 90.08%
FY18Y/Y Change
Total Assets
2.7B
↑ 101.8%
Total Liabilities
1.5B
↑ 63.91%
FY19Y/Y Change
Total Assets
3.2B
↑ 21.19%
Total Liabilities
1.5B
↑ 4.55%
FY20Y/Y Change
Total Assets
2.4B
↓ 26.07%
Total Liabilities
1.5B
↓ 0.06%
FY21Y/Y Change
Total Assets
2.6B
↑ 9.29%
Total Liabilities
1.8B
↑ 18.94%
FY22Y/Y Change
Total Assets
2.5B
↓ 2.99%
Total Liabilities
2.0B
↑ 6.58%
FY23Y/Y Change
Total Assets
3.0B
↑ 18.0%
Total Liabilities
2.6B
↑ 32.76%
Q1 FY23Q/Q Change
Total Assets
2.9B
↑ 13.85%
Total Liabilities
2.4B
↑ 22.28%
Q2 FY23Q/Q Change
Total Assets
3.0B
↑ 2.98%
Total Liabilities
2.5B
↑ 6.05%
Q3 FY23Q/Q Change
Total Assets
2.9B
↓ 1.25%
Total Liabilities
2.6B
↑ 2.99%
Q4 FY23Q/Q Change
Total Assets
3.0B
↑ 1.91%
Total Liabilities
2.6B
↓ 0.6%
Q1 FY24Q/Q Change
Total Assets
2.8B
↓ 7.56%
Total Liabilities
2.5B
↓ 5.22%
Q2 FY24Q/Q Change
Total Assets
2.7B
↓ 2.63%
Total Liabilities
2.4B
↓ 1.62%
FY18Y/Y Change
Operating Cash Flow
602.9M
↑ 246.19%
Investing Cash Flow
-929.6M
↑ 159.44%
Financing Cash Flow
475.9M
↑ 107.72%
FY19Y/Y Change
Operating Cash Flow
345.7M
↓ 42.66%
Investing Cash Flow
-41.3M
↓ 95.56%
Financing Cash Flow
100.0M
↓ 78.98%
FY20Y/Y Change
Operating Cash Flow
35.9M
↓ 89.62%
Investing Cash Flow
274.5M
↓ 765.01%
Financing Cash Flow
-596.6M
↓ 696.48%
FY21Y/Y Change
Operating Cash Flow
30.8M
↓ 14.19%
Investing Cash Flow
194.9M
↓ 28.99%
Financing Cash Flow
245.9M
↓ 141.22%
FY22Y/Y Change
Operating Cash Flow
-274.4M
↓ 990.84%
Investing Cash Flow
-262.6M
↓ 234.75%
Financing Cash Flow
-55.3M
↓ 122.48%
Q1 FY23Q/Q Change
Operating Cash Flow
-134.0M
↓ 33.07%
Investing Cash Flow
-325.6M
↓ 253.5%
Financing Cash Flow
492.1M
↓ 1064.52%
Q2 FY23Q/Q Change
Operating Cash Flow
-97.4M
↓ 27.34%
Investing Cash Flow
69.5M
↓ 121.35%
Financing Cash Flow
143.5M
↓ 70.83%

Technicals Summary

Sell

Neutral

Buy

Ionis Pharmaceuticals, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
-5.14%
-3.38%
-13.34%
30.83%
-28.19%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
524.14
NA
25.7
-3.67
-1.06
-0.08
NA
1.81
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Buy
$6.1B
-28.19%
524.14
-44.96%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Ionis Pharmaceuticals, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 119.49M → 225.25M (in $), with an average increase of 47.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -142.80M → -66.26M (in $), with an average increase of 115.5% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 96.9%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 14.0%

Institutional Holdings

  • FMR Inc

    13.88%

  • Vanguard Group Inc

    8.78%

  • T. Rowe Price Investment Management,Inc.

    8.01%

  • BlackRock Inc

    6.54%

  • Bellevue Group AG

    5.24%

  • Wellington Management Company LLP

    4.17%

Company Information

ionis pharmaceuticals, inc., located in the north san diego county city of carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. we are the pioneer in the discovery and development of antisense drugs with more than 1300 patents. ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. we are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. join us and experience our unique culture while you develop and expand your career. for more information about ionis and to apply for an open position, please visit our website: www.ionispharma.com.

Organization
Ionis Pharmaceuticals, Inc.
Employees
927
CEO
Dr. Brett P. Monia Ph.D.
Industry
Health Technology

Discover More

FAQs